公开(公告)号：US11795202B2

公开(公告)日：2023-10-24

申请号：US16322786

申请日：2017-08-04

Applicant: STICHTING VUMC

Inventor： Arjan Willem Griffioen ,  Elisabeth Johanna Maria Huijbers ,  Patrycja Nowak-Sliwinska

IPC: A61K39/00 ,  C07K14/47 ,  A61P35/00 ,  C07K14/245 ,  C07K14/78 ,  C07K16/18 ,  C12N15/62 ,  C12Q1/6886

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/245 ,  C07K14/78 ,  C07K16/18 ,  C12N15/62 ,  C12Q1/6886 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6068 ,  C07K2319/21 ,  C07K2319/35 ,  C12Q2600/106 ,  C12Q2600/112

Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.

公开(公告)号：US20230340045A1

公开(公告)日：2023-10-26

申请号：US18186724

申请日：2023-03-20

Applicant: STICHTING VUMC

Inventor： Arjan Willem GRIFFIOEN ,  Elisabeth Johanna Maria Huijbers ,  Patrycja Nowak-Sliwinska

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/245 ,  C07K14/78 ,  C07K16/18 ,  C12N15/62 ,  C12Q1/6886

CPC classification number: C07K14/4748 ,  A61P35/00 ,  A61K39/0011 ,  C07K14/245 ,  C07K14/78 ,  C07K16/18 ,  C12N15/62 ,  C12Q1/6886 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6068 ,  C07K2319/21 ,  C07K2319/35 ,  C12Q2600/106 ,  C12Q2600/112

Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.